Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGFR-targeted UCAR-T cell injection
- Development stage
- Unknown
- Lead developer
- Zhongshan People's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EGFR-targeted UCAR-T cell injection is an allogeneic (universal) chimeric antigen receptor T-cell therapy designed to target the epidermal growth factor receptor (EGFR). Unlike autologous CAR-T therapies, UCAR-T cells are derived from healthy donors and engineered to be used off-the-shelf by reducing the risk of graft-versus-host disease (GvHD) and immune rejection. This specific candidate is being evaluated in Phase 1 clinical trials for the treatment of advanced high-grade gliomas, such as glioblastoma, where EGFR is frequently overexpressed or mutated. The therapy aims to provide a potent, targeted immune response against tumor cells while overcoming the logistical and manufacturing challenges associated with patient-specific CAR-T products.
- Other names
- EGFR-targeted UCAR-TEGFR-UCAR-T
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on EGFR-targeted UCAR-T cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGFR-targeted UCAR-T cell injection.